SCHEMBL21980365

SCHEMBL21980365

COc1ccc(-c2noc(-c3cccc(Cl)c3)n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 13/20 0.74
▸ MAPT P10636 9/20 0.74
▸ SMN1; SMN2 Q16637 7/20 0.74
▸ TSHR P16473 2/20 0.74
▸ RAB9A P51151 11/20 0.72
▸ NR1H4 Q96RI1 2/20 0.69
▸ S1PR1 P21453 1/20 0.69
▸ TP53 P04637 2/20 0.69
▸ MEN1 O00255 2/20 0.68
▸ KMT2A Q03164 2/20 0.68
▸ NFKB1 P19838 1/20 0.66
▸ NFKB2 Q00653 1/20 0.66
▸ RELA Q04206 1/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ NPSR1 Q6W5P4 1/20 0.61
▸ LMNA P02545 2/20 0.59
▸ KDM4E B2RXH2 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ HPGD P15428 2/20 0.59
▸ HSD17B10 Q99714 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12692350 0.87 NPC1 (0.86) NPC1MAPTSMN1; SMN2TSHRRAB9A
SCHEMBL12420290 0.84 TP53 (0.75) NPC1MAPTSMN1; SMN2TSHRRAB9A
SCHEMBL16592626 0.84 NPC1 (0.64) NPC1MAPTSMN1; SMN2TSHRRAB9A
SCHEMBL26095707 0.84 RAB9A (1.00) NPC1MAPTSMN1; SMN2TSHRRAB9A
SCHEMBL7291752 0.82 NR1H4 (1.00) NPC1MAPTSMN1; SMN2RAB9ANR1H4
SCHEMBL6697420 0.82 NR1H4 (1.00) NPC1MAPTSMN1; SMN2RAB9ANR1H4
SCHEMBL12895918 0.82 RAB9A (0.76) NPC1MAPTSMN1; SMN2RAB9ANR1H4
SCHEMBL12692467 0.81 NR1H4 (0.66) NPC1MAPTSMN1; SMN2RAB9ANR1H4
SCHEMBL21282194 0.80 NPC1 (0.56) NPC1MAPTSMN1; SMN2TSHRRAB9A
SCHEMBL1430178 0.80 NR1H4 (0.68) NPC1MAPTSMN1; SMN2RAB9ANR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-07-17 — — US claimed
EP-4173485-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-03 — — EP claimed
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-07-17 — — US disclosed
EP-3634403-B1 PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA MAX PLANCK GESELLSCHAFT (DE) 2025-06-25 — — EP disclosed
WO-2023073115-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-04 — — WO disclosed
EP-4173485-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-03 — — EP disclosed
EP-4173485-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-03 — — EP disclosed
US-11180518-B2 Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-11-23 — — US disclosed
US-11180518-B2 Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-11-23 — — US disclosed
US-20200165279-A1 PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2020-05-28 — — US disclosed
US-20200165279-A1 PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2020-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165279-A1 PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA TYR, MITF, VHL NPC1 1279/4885MAPT 3145/4885SMN1; SMN2 3485/4885
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL APP, APBA1, PRNP NPC1 2456/4885MAPT 8/4885SMN1; SMN2 4191/4885
US-11180518-B2 Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma TYR, MITF, VHL NPC1 1279/4885MAPT 3145/4885SMN1; SMN2 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback